AGN - Allergan plc

NYSE - NYSE Delayed Price. Currency in USD
191.31
-1.20 (-0.62%)
At close: 4:03PM EDT
Stock chart is not supported by your current browser
Previous Close192.51
Open192.60
Bid181.12 x 800
Ask0.00 x 1000
Day's Range190.68 - 193.80
52 Week Range142.81 - 217.00
Volume5,893,797
Avg. Volume1,686,239
Market Cap64.939B
Beta1.37
PE Ratio (TTM)N/A
EPS (TTM)-5.32
Earnings DateOct 30, 2018 - Nov 5, 2018
Forward Dividend & Yield2.88 (1.52%)
Ex-Dividend Date2018-08-16
1y Target Est211.58
Trade prices are not sourced from all markets
  • 4 Stocks John Paulson and Paul Tudor Jones Agree On
    GuruFocus.comyesterday

    4 Stocks John Paulson and Paul Tudor Jones Agree On

    Gurus see value in 2 pharmaceutical companies, a chipmaker and an asset manager

  • Why an Exton pharma firm will benefit from Almirall's $550M deal with Allergan
    American City Business Journals2 days ago

    Why an Exton pharma firm will benefit from Almirall's $550M deal with Allergan

    The finalized deal between Almirall and Allergan involves four approved products and one under FDA review

  • 3 Drug/Biotech Stocks in Focus on World Alzheimer's Day
    Zacks2 days ago

    3 Drug/Biotech Stocks in Focus on World Alzheimer's Day

    We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.

  • Estimates and Recommendations for Shire on September 19
    Market Realist2 days ago

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017. Analysts expect Shire’s net adjusted income to increase to $4.68 billion in 2018 compared to its net adjusted income of $4.60 billion in 2017. Shire’s stock price has risen nearly 15.4% in the last 12 months, and it’s risen ~15.7% year-to-date in 2018.

  • The Wall Street Journal2 days ago

    [$$] Gormley's Take: Future of Aesthetic Medicine Not Just Another Pretty Face

    Botox has grown into a giant product thanks largely to older people seeking wrinkle treatments. Total sales of the treatment, which is also used for medical purposes, neared $1 billion in the second quarter. Now corporations and venture firms aim to provide aesthetic products to younger consumers.

  • Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates
    Market Realist3 days ago

    Pharma Stocks: Allergan’s Revenue Trend and 2018 Estimates

    Allergan (AGN) reported revenue of $4.1 billion in the second quarter, a 2.9% YoY (year-over-year) rise in revenue compared to its revenue of $4.0 billion in the second quarter of 2017.

  • Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st
    PR Newswire3 days ago

    Allergan Teams Up with Actor Scott Eastwood to Encourage Recognition of World Alzheimer's Day on September 21st

    DUBLIN, Sept. 20, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced a partnership with actor Scott Eastwood in honor of World Alzheimer's Day, September 21, a day used as a focal point by organizations globally to raise awareness for Alzheimer's disease and the sacrifices caregivers make every day for their loved ones. Through combined efforts, Allergan and Scott Eastwood hope to widely deliver the message that it is important for those affected by Alzheimer's to be well-informed, pointing to Allergan's educational website LearnAboutAlz.com as a resource.

  • Allergan Announces Plans to Build First Medical Aesthetics Innovation Center in Chengdu China
    PR Newswire4 days ago

    Allergan Announces Plans to Build First Medical Aesthetics Innovation Center in Chengdu China

    CHENGDU, China, Sept. 19, 2018 /PRNewswire/ -- Allergan, a global pharmaceutical company and leader in medical aesthetics, today announced plans to open its first Medical Aesthetics Innovation Center in Chengdu China in early 2019. The center, to be located at the High-Tech Zone of Chengdu, will feature a world-class training center for medical aesthetics healthcare professionals, as well as an education and product experience center for medical aesthetics consumers.

  • Pharma Stocks in Review: A Valuation Comparison
    Market Realist4 days ago

    Pharma Stocks in Review: A Valuation Comparison

    In this article, we’ll compare the valuations of Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • InvestorPlace4 days ago

    Teva Wins Approval From FDA for Blockbuster Migraine Drug

    Prospects are looking brighter for Teva Pharmaceuticals Industries Limited (NYSE:TEVA). The company won a pair of FDA approvals in September. The big news here is the FDA approving its migraine treatment.

  • A Review of Pharma Stocks’ EPS Growth Rates
    Market Realist5 days ago

    A Review of Pharma Stocks’ EPS Growth Rates

    In this article, we’ll compare the EPS growth rates of pharmaceutical companies Eli Lilly and Company (LLY), Pfizer (PFE), Merck & Co. (MRK), Allergan (AGN), and GlaxoSmithKline (GSK).

  • Benzinga5 days ago

    JMP: Changing Competitive Landscape Makes Revance Less Appealing

    Revance Therapeutics Inc (NASDAQ: RVNC ), a biotech company developing a botulinum toxin product, could face a competitive backlash, according to JMP Securities. The Analyst Analyst Donald Ellis downgraded ...

  • These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018
    Market Realist5 days ago

    These Pharmaceutical Stocks Have Surpassed the S&P 500 in 2018

    The US pharmaceutical sector is made up of players that include drug manufacturers, drug marketers, and biotechnology companies.

  • Allergan Frown Lines Study Passes Test on Higher Botox Dose
    Zacks6 days ago

    Allergan Frown Lines Study Passes Test on Higher Botox Dose

    Allergan (AGN) presents positive results from a study, evaluating a higher dose of Botox for the treatment of glabellar lines.

  • PR Newswire8 days ago

    Allergan Announces Results of Higher Dose BOTOX® Cosmetic (onabotulinumtoxinA) for the Treatment of Moderate to Severe Glabellar Lines

    DUBLIN, Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today announced clinical study results of higher doses of BOTOX® Cosmetic compared to BOTOX® Cosmetic 20 unit dose at week 24 in patients with moderate to severe glabellar lines.

  • FDA plans meeting to discuss safety data on breast implants
    Associated Press8 days ago

    FDA plans meeting to discuss safety data on breast implants

    U.S. health regulators say they'll convene a public meeting of medical advisers next year to discuss new science on breast implant safety, including an independent analysis that suggests certain rare health problems might be more common with silicone gel implants.

  • PR Newswire8 days ago

    Allergan Highlights Key Growth Drivers for Medical Aesthetics

    DUBLIN, Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN) today hosted its first ever Medical Aesthetics Analyst Day where the Company outlined its industry-leading portfolio and pipeline and key initiatives to drive future growth, as well as presented an overview of the global medical aesthetics market.

  • Allergan says revenue from aesthetics unit may double by 2025
    Reuters8 days ago

    Allergan says revenue from aesthetics unit may double by 2025

    Allergan Plc (AGN.N) said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox. The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox. Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc (RVNC.O) and Evolus Inc (EOLS.O) vie to wrest market share with rival treatments to Botox.

  • Allergan says revenue from aesthetics unit may double by 2025
    Reuters8 days ago

    Allergan says revenue from aesthetics unit may double by 2025

    The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox. Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox. The company made the announcements at its Medical Aesthetics Day in New York.

  • The Wall Street Journal8 days ago

    [$$] The Curious New Botox Ads

    ’s 2008 hit, “I Kissed a Girl.” Potential customers viewing the ad likely won’t need any medical treatment to raise their eyebrows. The ad fits with Allergan’s effort to boost sales of Botox by marketing it to younger people and to men.

  • Who Really Owns Allergan plc (NYSE:AGN)?
    Simply Wall St.8 days ago

    Who Really Owns Allergan plc (NYSE:AGN)?

    A look at the shareholders of Allergan plc (NYSE:AGN) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual toRead More...

  • The Wall Street Journal9 days ago

    [$$] Allergan Acquires Neurotoxins Startup Bonti

    Allergan PLC said Friday it would acquire neurotoxin product developer Bonti Inc. for an up-front payment of $195 million.

  • Is Allergan (AGN) a Great Stock for Value Investors?
    Zacks9 days ago

    Is Allergan (AGN) a Great Stock for Value Investors?

    Let's see if Allergan (AGN) stock is a good choice for value-oriented investors right now from multiple angles.

  • PR Newswire9 days ago

    Allergan to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics Pipeline

    DUBLIN and NEWPORT BEACH, Calif., Sept. 14, 2018 /PRNewswire/ -- Allergan plc (AGN), a leading global pharmaceutical company, today announced it has agreed to acquire Bonti, Inc., a privately held clinical-stage biotechnology company focused on the development and commercialization of novel, fast-acting neurotoxin programs for aesthetic and therapeutic applications. Following completion of the acquisition, Allergan will obtain global rights to Bonti's pipeline consisting of two botulinum neurotoxin serotype E (BoNT/E) programs currently in Phase 2 development, EB-001A (aesthetic) and EB-001T (therapeutic).